Lip Cancer - Pipeline Review, H2 2012

Lip Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Lip Cancer - Pipeline Review, H2 2012', provides an overview of the Lip Cancer therapeutic pipeline. This report provides information on the therapeutic development for Lip Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lip Cancer. 'Lip Cancer - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Lip Cancer.
- A review of the Lip Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Lip Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Lip Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Lip Cancer pipeline depth and focus of Lip Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Lip Cancer Therapeutic Products under Development, Key Players in Lip Cancer Therapeutics, Lip Cancer Pipeline Overview, Lip Cancer Pipeline, Lip Cancer Pipeline Assessment SHOW LESS READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Lip Cancer Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Lip Cancer 7
Lip Cancer Therapeutics under Investigation by Universities/Institutes 9
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Lip Cancer Therapeutics – Products under Investigation by Universities/Institutes 14
Lip Cancer – Therapeutics Assessment 15
Assessment by Monotherapy Products 15
Assessment by Combination Products 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Drug Profiles 21
HPPH - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Tarceva - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Cetuximab + Cisplatin + Radiation Therapy - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 26
Cisplatin + Cytochlor + Tetrahydrouridine + Radiation Therapy - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Filgrastim + Palifermin + Cyclophosphamide + Etoposide + Ifosfamide - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 30
Erlotinib Hydrochloride + Radiation Therapy - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Lapatinib Ditosylate + Capecitabine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Erbitux + Radiation Therapy - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Curcumin - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Docetaxel + Nedaplatin - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Erlotinib Hydrochloride + Linsitinib - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Erlotinib Hydrochloride - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Linsitinib - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Lip Cancer Therapeutics – Discontinued Products 44
Lip Cancer Therapeutics - Dormant Products 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

List of Tables
Number of Products Under Development for Lip Cancer, H2 2012 7
Products under Development for Lip Cancer – Comparative Analysis, H2 2012 8
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
Assessment by Monotherapy Products, H2 2012 15
Assessment by Combination Products, H2 2012 16
Assessment by Stage and Route of Administration, H2 2012 18
Assessment by Stage and Molecule Type, H2 2012 20
Lip Cancer Therapeutics – Discontinued Products 44
Lip Cancer Therapeutics – Dormant Products 45

List of Figures
Number of Products under Development for Lip Cancer, H2 2012 7
Products under Development for Lip Cancer – Comparative Analysis, H2 2012 8
Products under Investigation by Universities/Institutes, H2 2012 9
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 15
Assessment by Combination Products, H2 2012 16
Assessment by Route of Administration, H2 2012 17
Assessment by Stage and Route of Administration, H2 2012 18
Assessment by Molecule Type, H2 2012 19
Assessment by Stage and Molecule Type, H2 2012 20